<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01681446</url>
  </required_header>
  <id_info>
    <org_study_id>LCI IFNa miR-26</org_study_id>
    <nct_id>NCT01681446</nct_id>
  </id_info>
  <brief_title>The Effect of Postoperative Interferon- Alpha Treatment in Low miR-26 Expression Patients With HCC</brief_title>
  <official_title>The Effect of Postoperative Interferon- Alpha Treatment in Low miR-26 Expression Patients With Hepatocellular Carcinoma: a Muti-center Randomized Clinical Trail.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether interferon-alpha is effective in the
      treatment of low miR-26 expression patients with HCC after curative resection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND: Postoperative interferon-alpha (IFN-alpha) therapy improved survival in patients
      with hepatocellular carcinoma (HCC). MiR-26 is a predictive marker for the efficiency of
      postoperative interferon-alpha treatment in patients with HCC. Our study is to identify the
      Efficiency of Postoperative IFN-Alpha Treatment in low miR-26 expression Patients With HCC.

      METHODS: A quantitative reverse-transcriptase-polymerase-chain-reaction assays of miR-26 are
      performed on specimens which are collected from patients who underwent a curative resection
      of HCC. These patients with low miR-26 expression will return to the hospital 25±5 days after
      the resection following the baseline examination. If all requirements are satisfied, these
      patients will be randomly divided into the treatment group who received postoperative
      IFN-alpha therapy or the comparison group who not received any treatment. Besides the
      disease-free survival rate, the overall survival rate, time to recurrence and the side effect
      will be observed.

      Anticipated RESULTS: IFN alpha treatment improved the disease-free survival and the overall
      survival in low miR-26 expression patients with HCC after curative resection, probably by
      postponing recurrence.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease free survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to recurrence</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>eighteen months</time_frame>
    <description>Number of Participants with Adverse Events（hypohepatia,fever,leukopenia and thrombopenia）will be measured</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">506</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>interferon-alpha (IFN-alpha)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the interferon-alpha is intramuscular injected 3,000,000U three times a week for 18 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no interventions were assigned</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>interferon-alpha (IFN-alpha)</intervention_name>
    <description>interferon-alpha is intramuscularly or subcutaneously injected at 3,000,000-5,000,000 U three times a week for 18 months</description>
    <arm_group_label>interferon-alpha (IFN-alpha)</arm_group_label>
    <other_name>Recombinant Human Interferon α1b for Injection</other_name>
    <other_name>SINOGEN</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Perioperative Period Inclusion Criteria:

          1. Signed informed consent;

          2. Aged ≥ 18 years and ≤ 75 years old, male or female；

          3. Patients with low miR-26 expression(confirmed by RT-PCR) underwent a curative
             resection of HCC;

          4. The tumor characteristics must meet the following:

               1. tumor diameter is between 3 to 8 centimeters,and the number of tumor is less tnan
                  3

               2. no thrombosis is detected in the main branches of the portal vein, hepatic vein
                  and bile duct

               3. no extrahepatic and lymphnode metastasis

        Perioperative Period Exclusion Criteria:

          1. Concomitant malignant primary tumor(s) in other systems is/are present;

          2. The subject receives any previous systemic anti-HCC therapy prior to the resection
             surgery (except the resection surgery), such as liver transplantation, intervention,
             ablation, radiotherapy, chemotherapy, molecular targeted therapy or other anti-HCC
             therapy;

          3. The subject takes other study/investigational drugs during this study;

          4. The subject has cerebrovascular accident, renal insufficiency, depression,
             hyperthyreosis, hypothyroidism or other severe uncontrolled diseases;

          5. The subject has a history of study drug or similar drug allergy.

        Baseline (Post-SurgeryDay 25 ± 5) Inclusion Criteria:

          1. Baseline (post-resection) blood routine examination shows that the number of
             leukocyte&gt;2.5*10^9/L and platelet count&gt;40*10^9/L;

          2. Child-Pugh score of class A at baseline.

        Baseline (Post-SurgeryDay 25 ± 5) Exclusion Criteria:

          1. Concomitant malignant primary tumor(s) in other systems is/are present;

          2. The subject takes other study/investigational drugs within 4 weeks prior to
             randomization;

          3. The baseline examination indicates that infection, bleeding, bile leakage, or other
             postoperative complications are present;

          4. The baseline examination suggests the presence of tumor metastasis;

          5. The subject has cerebrovascular accident, renal insufficiency, depression,
             hyperthyreosis, hypothyroidism or other severe uncontrolled diseases;

          6. The subject has a history of investigational drug or similar drug allergy;

          7. The subject is pregnant, lactating, or urine pregnancy test result is positive.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jia Fan, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xin Wei Wang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, NIH, US</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mei-ling Li</last_name>
    <phone>64041990</phone>
    <phone_ext>2936</phone_ext>
    <email>livercongress@zs-hospital.sh.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hai-Tao Zhao, MD</last_name>
      <email>zhaoht@yahoo.cn</email>
    </contact>
    <investigator>
      <last_name>Yi-Lei Mao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hai-Tao Zhao, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fujian Tumor Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong Zhou, MD</last_name>
    </contact>
    <investigator>
      <last_name>Min-Gang Ying, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dong Zhou, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Mengchao hepatobiliary hospital，Fujian Medical University，and Liver disease research center of Fujian province</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jingfeng Liu</last_name>
      <email>drjingfeng@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>Jingfeng Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tumor Hospital, Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Xu, MD</last_name>
      <email>xuli@sysucc.org.cn</email>
    </contact>
    <investigator>
      <last_name>Min-Shan Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Li Xu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eastern Hepatobiliary Surgery Hospital, the Chinese Second Military Medical University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feng Shen, MD, PhD</last_name>
      <email>shenfengdfgd@yahoo.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Feng Shen, MD, PhD</last_name>
      <email>shenfengdfgd@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Feng Shen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tumor Hospital, Tianjin Medical University</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ti Zhang, MD</last_name>
      <email>zhangti2001@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>Qiang Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ti Zhang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liver Cancer Institute and Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mei-ling Li</last_name>
      <phone>64041990</phone>
      <phone_ext>2936</phone_ext>
      <email>livercongress@zs-hospital.sh.cn</email>
    </contact>
    <investigator>
      <last_name>Jia Fan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hui-Chuan Sun, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ShanghaiBio Coorperation</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Gang Jin, PhD</last_name>
      <phone>13818588366</phone>
      <email>jasongjin@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jason Gang Jin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, Ambs S, Chen Y, Meltzer PS, Croce CM, Qin LX, Man K, Lo CM, Lee J, Ng IO, Fan J, Tang ZY, Sun HC, Wang XW. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med. 2009 Oct 8;361(15):1437-47. doi: 10.1056/NEJMoa0901282.</citation>
    <PMID>19812400</PMID>
  </reference>
  <reference>
    <citation>Sun HC, Tang ZY, Wang L, Qin LX, Ma ZC, Ye QH, Zhang BH, Qian YB, Wu ZQ, Fan J, Zhou XD, Zhou J, Qiu SJ, Shen YF. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol. 2006 Jul;132(7):458-65. Epub 2006 Mar 24.</citation>
    <PMID>16557381</PMID>
  </reference>
  <reference>
    <citation>Lo CM, Liu CL, Chan SC, Lam CM, Poon RT, Ng IO, Fan ST, Wong J. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg. 2007 Jun;245(6):831-42.</citation>
    <PMID>17522506</PMID>
  </reference>
  <reference>
    <citation>Clavien PA. Interferon: the magic bullet to prevent hepatocellular carcinoma recurrence after resection? Ann Surg. 2007 Jun;245(6):843-5.</citation>
    <PMID>17522507</PMID>
  </reference>
  <reference>
    <citation>Qian YB, Zhang JB, Wu WZ, Fang HB, Jia WD, Zhuang PY, Zhang BH, Pan Q, Xu Y, Wang L, Tang ZY, Sun HC. P48 is a predictive marker for outcome of postoperative interferon-alpha treatment in patients with hepatitis B virus infection-related hepatocellular carcinoma. Cancer. 2006 Oct 1;107(7):1562-9.</citation>
    <PMID>16948122</PMID>
  </reference>
  <reference>
    <citation>Wang L, Tang ZY, Qin LX, Wu XF, Sun HC, Xue Q, Ye SL. High-dose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. Hepatology. 2000 Jul;32(1):43-8.</citation>
    <PMID>10869287</PMID>
  </reference>
  <reference>
    <citation>Wang L, Wu WZ, Sun HC, Wu XF, Qin LX, Liu YK, Liu KD, Tang ZY. Mechanism of interferon alpha on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice. J Gastrointest Surg. 2003 Jul-Aug;7(5):587-94.</citation>
    <PMID>12850669</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2012</study_first_submitted>
  <study_first_submitted_qc>September 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2012</study_first_posted>
  <last_update_submitted>February 2, 2016</last_update_submitted>
  <last_update_submitted_qc>February 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Jia Fan</investigator_full_name>
    <investigator_title>Professor of Surgery</investigator_title>
  </responsible_party>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>interferon-alpha</keyword>
  <keyword>miR-26</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

